Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 7,767 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo; placebo comparator condition Clear all
Completed Phase 1Phase 2 Interventional Results available

Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation

NCT04539262
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir (RDV), Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
28
States / cities
Mesa, Arizona • Tucson, Arizona • Bakersfield, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 14, 2026, 1:18 PM EDT
Completed Phase 2 Interventional Results available

Study of VVN001 Ophthalmic Solution in Dry Eye Disease

NCT04556838
View directory record Official record
Conditions
Dry Eye
Interventions
VVN001 Ophthalmic Solution 1%, VVN001 Ophthalmic Solution 5%, Vehicle
Drug
Lead sponsor
VivaVision Biotech, Inc
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 14, 2026, 1:18 PM EDT
Completed Phase 2 Interventional

A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease

NCT01609140
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
MPSK3169A, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
34
States / cities
Goodyear, Arizona • Carmichael, California • Spring Valley, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 14, 2026, 1:18 PM EDT
Completed Phase 4 Interventional Results available

Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression

NCT00607789
View directory record Official record
Conditions
Binge Eating, Depression
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 14, 2026, 1:18 PM EDT
Terminated Not applicable Interventional Results available

Effects of Flibanserin on the Pre- and Post-menopausal Female Brain

NCT02770768
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Flibanserin, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 74 Years · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 14, 2026, 1:18 PM EDT
Completed Phase 3 Interventional Results available

Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease

NCT02968368
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Iron-Deficiency Anemia
Interventions
Ferric maltol, Placebo
Drug · Other
Lead sponsor
Shield Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
27
States / cities
Peoria, Arizona • Phoenix, Arizona • Prescott, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 14, 2026, 1:18 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

NCT07145918
View directory record Official record
Conditions
Schizophrenia
Interventions
Emraclidine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Little Rock, Arkansas • Glendale, California • Los Alamitos, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 14, 2026, 1:18 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

NCT05760313
View directory record Official record
Conditions
Functional Constipation
Interventions
Linaclotide, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Months to 23 Months
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Anaheim, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 14, 2026, 1:18 PM EDT
Terminated Phase 2 Interventional Results available

A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

NCT03919162
View directory record Official record
Conditions
Alzheimer Disease
Interventions
PQ912, Placebo
Drug · Other
Lead sponsor
Vivoryon Therapeutics N.V.
Industry
Eligibility
50 Years to 89 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Phoenix, Arizona • Sun City, Arizona • Chula Vista, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 14, 2026, 1:18 PM EDT
Completed Early Phase 1 Interventional

Metformin Treatment in Progressive Multiple Sclerosis

NCT05349474
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions
Metformin 500 Mg Oral Tablet, up to 4 tablets a day, Placebo oral tablet identical to metformin, up to 4 tablets a day
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
30 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 14, 2026, 1:18 PM EDT
Completed Phase 2 Interventional Results available

A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

NCT04480710
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, NAFLD - Nonalcoholic Fatty Liver Disease
Interventions
CRV431 75mg, Placebo (1 softgel), CRV431 225mg, Placebo (3 softgels)
Drug
Lead sponsor
Hepion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Orange, California • Poway, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2022 · Synced Oct 14, 2026, 1:18 PM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT02704403
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Interventions
Elafibranor, Placebo
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 75 Years
Enrollment
2,157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
153
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Oct 14, 2026, 1:18 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT04985942
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lumateperone, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
15
States / cities
Phoenix, Arizona • Glendale, California • Oceanside, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 14, 2026, 1:18 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

NCT04641442
View directory record Official record
Conditions
NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations
Interventions
MAS825, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
0 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
4
States / cities
Cincinnati, Ohio • Philadelphia, Pennsylvania • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 14, 2026, 1:18 PM EDT
Completed Phase 3 Interventional Results available

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

NCT01718483
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
43
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Corona, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 14, 2026, 1:18 PM EDT
Completed Phase 2 Interventional Results available

A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease

NCT03384966
View directory record Official record
Conditions
Stable Coronary Artery Disease
Interventions
Selatogrel, Placebo
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 85 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
7
States / cities
Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 14, 2026, 1:18 PM EDT
Recruiting Phase 2 Interventional

A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07643766
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ENV-294, Placebo
Drug · Other
Lead sponsor
Enveda Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Encinitas, California • Los Angeles, California • Northridge, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 14, 2026, 1:18 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Phase 2 Study of Apremilast in Women and Men With Alcohol Use Disorder

NCT07029529
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Apremilast 60mg, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 14, 2026, 1:18 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment

NCT02809118
View directory record Official record
Conditions
Hearing Loss, Idiopathic Sudden Sensorineural
Interventions
AM-111 0.4 mg/ml, AM-111 0.8 mg/ml, Placebo
Drug · Other
Lead sponsor
Auris Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
38
States / cities
Birmingham, Alabama • Escondido, California • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2020 · Synced Oct 14, 2026, 1:18 PM EDT
Completed Phase 3 Interventional

Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)

NCT00062582
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD
Interventions
Roflumilast
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
32
States / cities
Cities in Alabama, Alabama • Cities in Arizona, Arizona • Cities in California, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 14, 2026, 1:18 PM EDT
Not listed Phase 3 Interventional

Study for Treatment of Moderate or Severe, Periodic, "Cyclic", Breast Pain

NCT00237523
View directory record Official record
Conditions
Fibrocystic Disease of Breast, Fibrocystic Changes of Breast, Fibrocystic Mastopathy, Pain
Interventions
IoGen (molecular iodine)
Drug
Lead sponsor
Symbollon Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
39
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2007 · Synced Oct 14, 2026, 1:18 PM EDT
Terminated Phase 3 Interventional

Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures

NCT00060996
View directory record Official record
Conditions
Critical Limb Ischemia, Peripheral Vascular Disease, Foot Ulcers, Rest Leg Pain
Interventions
Remodulin® (treprostinil sodium) Injection
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
7
States / cities
Tampa, Florida • Worcester, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 14, 2026, 1:18 PM EDT
Completed Phase 4 Interventional Results available

The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease

NCT03829046
View directory record Official record
Conditions
Atherosclerotic Vascular Disease, Type2 Diabetes, Microvascular Dysfunction
Interventions
Placebo, Evolocumab
Drug
Lead sponsor
Robert Rosenson
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 14, 2026, 1:18 PM EDT
Completed Phase 2 Interventional

Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease

NCT00740103
View directory record Official record
Conditions
Crohn's Disease
Interventions
Semapimod
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
8
States / cities
San Francisco, California • Atlanta, Georgia • Suwanee, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 14, 2026, 1:18 PM EDT